![Sarah Noonberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sarah Noonberg
Chief Tech/Sci/R&D Officer at
ABCELLERA BIOLOGICS INC.
Net worth: 129 871 $ as of 2026-06-29
Profile
Sarah B. Noonberg is currently an Independent Director at Neurogene, Inc. since 2023 and Chief Medical Officer at AbCellera Biologics, Inc. starting in 2025.
Former roles include Independent Director at Protagonist Therapeutics, Inc. from 2017 to 2023, Independent Director at Neoleukin Therapeutics, Inc. from 2019 to 2023, Independent Director at Immedica Pharma US, Inc. from 2023 to 2024, Chief Medical Officer at Metagenomi Therapeutics, Inc. from 2023 to 2025, Chief Medical Officer at Maze Therapeutics, Inc. from 2020 to 2022, Chief Medical Officer at Nohla Therapeutics, Inc. from 2018 to 2019, Chief Medical Officer at Prothena Corp.
Plc from 2017 to 2018, Group VP & Head-Global Clinical Development at BioMarin Pharmaceutical, Inc. from 2015 to 2017, Director-Clinical Development at Chiron Corp.
from 2004 to 2007, Director at Aquinox Pharmaceuticals, Inc., Director at Neoleukin Therapeutics, Inc., Senior Vice President-Early Development at Medivation, Inc., and Chief Medical Officer at Metagenomi Technologies LLC.
Education includes undergraduate studies at Dartmouth College, doctorate degrees from the University of California, Berkeley and The University of California, San Francisco, and graduate studies at the University of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-06-05 | 109,135 ( 0.29% ) | 129 871 $ | 2026-06-29 | |
-.--% | 2026-04-06 | 0 ( -.--% ) | - $ | 2026-06-29 |
Sarah Noonberg active positions
| Companies | Position | Start |
|---|---|---|
| ABCELLERA BIOLOGICS INC. | Chief Tech/Sci/R&D Officer | 2025-09-09 |
Former positions of Sarah Noonberg
| Companies | Position | End |
|---|---|---|
| METAGENOMI THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2025-07-31 |
| MARINUS PHARMACEUTICALS, INC. | Director/Board Member | 2024-11-13 |
| NEUROGENE INC. | Director/Board Member | 2023-11-30 |
| PROTAGONIST THERAPEUTICS, INC. | Director/Board Member | 2023-05-24 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Chief Tech/Sci/R&D Officer | 2022-08-31 |
Training of Sarah Noonberg
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
69
1st degree connections
18
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 18 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Marinus Pharmaceuticals, Inc.
 Marinus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for rare genetic epilepsies and other seizure disorders | Health Technology |
Dartmouth College
 Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medivation, Inc. /Old/
 Medivation, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Health Technology |
Protagonist Therapeutics, Inc.
 Protagonist Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures peptide based therapeutic products | Health Technology |
University of California
 University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prothena Corp. Plc
 Prothena Corp. Plc BiotechnologyHealth Technology Focuses on the discovery and development of novel antibodies | Health Technology |
AbCellera Biologics, Inc.
 AbCellera Biologics, Inc. BiotechnologyHealth Technology Discovers and develops antibody drugs & therapeutics | Health Technology |
Nohla Therapeutics, Inc.
 Nohla Therapeutics, Inc. BiotechnologyHealth Technology Develops cellular therapies for hematological disorders | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Health Technology |
Neoleukin Therapeutics, Inc. /old/
 Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Develops medicines that transform lives | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
Metagenomi Technologies LLC
 Metagenomi Technologies LLC BiotechnologyHealth Technology Develops genetic medicines using metagenomics-powered genome editing toolbox | Health Technology |
Metagenomi, Inc.
 Metagenomi, Inc. Pharmaceuticals: MajorHealth Technology Operates as a genetic medicines company that develops curative therapeutics for patients | Health Technology |
- Stock Market
- Insiders
- Sarah Noonberg
